PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer
This research study is studying immunotherapy as a possible treatment for metastatic Triple Negative Breast Cancer (TNBC) in participants who are HLA-A2+.
The drugs involved in this study are:
A Phase 1b Study of Safety and Immune Response to PVX-410 Vaccine Alone and in Combination with Pembrolizumab in HLA-A2+ Patients with Metastatic Triple Negative Breast Cancer (TNBC)
- ClinicalTrials.gov Identifier: NCT03362060
- Protocol Number: 17-328
- Principal Investigator: Jaymin Patel
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required